ID   MM386
AC   CVCL_2607
SY   MM 386
DR   BioSample; SAMN07624428
DR   CBA; CBA-1349
DR   Cell_Model_Passport; SIDM01373
DR   Cosmic; 889020
DR   Cosmic; 928736
DR   Cosmic; 1418457
DR   DepMap; ACH-001568
DR   ECACC; 10092318
DR   GEO; GSM162932
DR   GEO; GSM226660
DR   IARC_TP53; 10957
DR   Progenetix; CVCL_2607
DR   Wikidata; Q54906119
RX   PubMed=9354451;
RX   PubMed=10070891;
RX   PubMed=15048078;
RX   PubMed=17363583;
RX   PubMed=17516929;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Sequence variation: Gene deletion; HGNC; 9588; PTEN; Zygosity=Homozygous (PubMed=17363583).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=15048078; PubMed=17363583; DepMap).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg290His (c.869G>A); ClinVar=VCV000127825; Zygosity=Unspecified (PubMed=10070891).
CC   Omics: CNV analysis.
CC   Omics: Deep exome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis.
CC   Derived from metastatic site: Lymph node.
ST   Source(s): CBA; DepMap
ST   Amelogenin: X,Y
ST   CSF1PO: 12,14
ST   D13S317: 8,12
ST   D16S539: 11
ST   D18S51: 12
ST   D19S433: 14
ST   D21S11: 30,32
ST   D2S1338: 26
ST   D3S1358: 15
ST   D5S818: 11,13
ST   D7S820: 8,9
ST   D8S1179: 13
ST   FGA: 20,22
ST   Penta D: 9,12
ST   Penta E: 11,12
ST   TH01: 6,8
ST   TPOX: 8,9
ST   vWA: 16,19
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 16-12-21; Version: 20
//
RX   PubMed=9354451;
RA   Castellano M., Pollock P.M., Walters M.K., Sparrow L.E., Down L.M.,
RA   Gabrielli B.G., Parsons P.G., Hayward N.K.;
RT   "CDKN2A/p16 is inactivated in most melanoma cell lines.";
RL   Cancer Res. 57:4868-4875(1997).
//
RX   PubMed=10070891; DOI=10.1038/sj.bjc.6690147;
RA   Zerp S.F., van Elsas A., Peltenburg L.T.C., Schrier P.I.;
RT   "p53 mutations in human cutaneous melanoma correlate with sun exposure
RT   but are not always involved in melanomagenesis.";
RL   Br. J. Cancer 79:921-926(1999).
//
RX   PubMed=15048078; DOI=10.1038/sj.onc.1207563;
RA   Pavey S., Johansson P., Packer L., Taylor J., Stark M.S., Pollock P.M.,
RA   Walker G.J., Boyle G.M., Harper U., Cozzi S.-J., Hansen K., Yudt L.,
RA   Schmidt C., Hersey P., Ellem K.A.O., O'Rourke M.G.E., Parsons P.G.,
RA   Meltzer P.S., Ringner M., Hayward N.K.;
RT   "Microarray expression profiling in melanoma reveals a BRAF mutation
RT   signature.";
RL   Oncogene 23:4060-4067(2004).
//
RX   PubMed=17363583; DOI=10.1158/0008-5472.CAN-06-4152;
RA   Stark M.S., Hayward N.K.;
RT   "Genome-wide loss of heterozygosity and copy number analysis in
RT   melanoma using high-density single-nucleotide polymorphism arrays.";
RL   Cancer Res. 67:2632-2642(2007).
//
RX   PubMed=17516929; DOI=10.1111/j.1600-0749.2007.00375.x;
RA   Johansson P., Pavey S., Hayward N.K.;
RT   "Confirmation of a BRAF mutation-associated gene expression signature
RT   in melanoma.";
RL   Pigment Cell Res. 20:216-221(2007).
//